BR112018077139A8 - Anticorpos anti-met e seus usos - Google Patents

Anticorpos anti-met e seus usos

Info

Publication number
BR112018077139A8
BR112018077139A8 BR112018077139A BR112018077139A BR112018077139A8 BR 112018077139 A8 BR112018077139 A8 BR 112018077139A8 BR 112018077139 A BR112018077139 A BR 112018077139A BR 112018077139 A BR112018077139 A BR 112018077139A BR 112018077139 A8 BR112018077139 A8 BR 112018077139A8
Authority
BR
Brazil
Prior art keywords
met
met antibodies
antibodies
hgf
effects
Prior art date
Application number
BR112018077139A
Other languages
English (en)
Other versions
BR112018077139A2 (pt
Inventor
Michieli Paolo
Original Assignee
Agomab Therapeutics Bvba
Agomab Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomab Therapeutics Bvba, Agomab Therapeutics filed Critical Agomab Therapeutics Bvba
Publication of BR112018077139A2 publication Critical patent/BR112018077139A2/pt
Publication of BR112018077139A8 publication Critical patent/BR112018077139A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Abstract

A invenção refere-se a anticorpos anti-MET agonistas e seus usos no tratamento terapêutico de doença. Os anticorpos ligam-se com elevada afinidade ao receptor do fator de crescimento de hepatócitos humano e de camundongo (HGF), também conhecido como MET, e são agonistas de MET em humanos e camundongos, produzindo efeitos moleculares e celulares que se assemelham aos efeitos da ligação de HGF.
BR112018077139A 2016-06-27 2017-06-23 Anticorpos anti-met e seus usos BR112018077139A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1611123.9 2016-06-27
GBGB1611123.9A GB201611123D0 (en) 2016-06-27 2016-06-27 Anti met antibodiesand uses thereof
PCT/EP2017/065599 WO2018001909A1 (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof

Publications (2)

Publication Number Publication Date
BR112018077139A2 BR112018077139A2 (pt) 2019-04-30
BR112018077139A8 true BR112018077139A8 (pt) 2022-12-13

Family

ID=56891586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018077139A BR112018077139A8 (pt) 2016-06-27 2017-06-23 Anticorpos anti-met e seus usos

Country Status (12)

Country Link
US (3) US11098126B2 (pt)
EP (2) EP3674321A3 (pt)
JP (2) JP7088853B2 (pt)
KR (3) KR102366667B1 (pt)
CN (2) CN109689687B (pt)
AU (1) AU2017288985B2 (pt)
BR (1) BR112018077139A8 (pt)
CA (1) CA3032496A1 (pt)
GB (1) GB201611123D0 (pt)
MX (1) MX2019000135A (pt)
RU (2) RU2765267C2 (pt)
WO (1) WO2018001909A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
KR102221755B1 (ko) * 2018-05-02 2021-03-02 (주)에임드바이오 c-Met에 특이적으로 결합하는 항체 및 그의 용도
JP2022521610A (ja) 2019-02-26 2022-04-11 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CN117157325A (zh) 2021-04-08 2023-12-01 拜奥迪斯私人有限公司 抗c-met抗体和抗体-药物缀合物
US20240173561A1 (en) 2021-05-21 2024-05-30 Emblation Limited Microwave treatment of tissue

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
IL127558A0 (en) 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN104804095A (zh) 2004-08-05 2015-07-29 健泰科生物技术公司 人源化抗c-met 拮抗剂
AU2007213804B2 (en) 2006-02-06 2012-12-13 Vertical Bio Ag Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
AU2011203499B2 (en) * 2006-03-30 2013-01-31 Novartis Ag Compositions and methods of use for antibodies of c-Met
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
AU2011325097B2 (en) * 2010-11-03 2015-05-21 Argenx Bvba Anti c-Met antibodies
CA2832113C (en) * 2011-04-02 2020-07-21 Washington State University Research Foundation Hepatocyte growth factor mimics as therapeutic agents
KR101444837B1 (ko) * 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
GB201121914D0 (en) * 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
KR101615619B1 (ko) 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CN108601834B (zh) 2016-02-05 2022-05-03 赫利世弥斯株式会社 抗间质-上皮细胞转化因子抗体及其用途
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000534A1 (it) 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.

Also Published As

Publication number Publication date
MX2019000135A (es) 2019-09-26
KR20230120678A (ko) 2023-08-17
KR102566845B1 (ko) 2023-08-14
CA3032496A1 (en) 2018-01-04
KR102366667B1 (ko) 2022-02-23
WO2018001909A1 (en) 2018-01-04
AU2017288985A1 (en) 2019-01-17
JP2019524085A (ja) 2019-09-05
RU2765267C2 (ru) 2022-01-27
US20190315873A1 (en) 2019-10-17
US20240132601A1 (en) 2024-04-25
EP3674321A3 (en) 2020-09-30
BR112018077139A2 (pt) 2019-04-30
RU2022101369A (ru) 2022-02-08
JP7088853B2 (ja) 2022-06-21
RU2018146419A (ru) 2020-06-26
US20220153850A1 (en) 2022-05-19
CN109689687A (zh) 2019-04-26
RU2018146419A3 (pt) 2020-09-30
EP3475302A1 (en) 2019-05-01
CN115057933A (zh) 2022-09-16
US11098126B2 (en) 2021-08-24
JP2022121461A (ja) 2022-08-19
AU2017288985B2 (en) 2024-05-16
GB201611123D0 (en) 2016-08-10
KR20220030306A (ko) 2022-03-10
CN109689687B (zh) 2022-07-15
EP3674321A2 (en) 2020-07-01
KR20190025938A (ko) 2019-03-12

Similar Documents

Publication Publication Date Title
BR112018077139A8 (pt) Anticorpos anti-met e seus usos
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
BR112019010943A8 (pt) Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
CL2019001324A1 (es) Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos.
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12015501493B1 (en) Anti-pdgfr-beta antibodies and uses thereof
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
BR112017020952A2 (pt) método de tratamento de câncer, composição e uso da composição
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
EA201790377A1 (ru) Антитела к глюкагону и их применения
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112016002164A2 (pt) anticorpos de antiactivina a e usos dos mesmos
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
BR112015022942A2 (pt) heterociclos tricíclicos como inibidores da proteína bet
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
MX2018006782A (es) Nuevos anticuerpos anti-claudina y sus metodos de uso.
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
BR112017028331A2 (pt) proteínas de fusão que se ligam a receptores fc humanos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: AGOMAB THERAPEUTICS (BE)

B25G Requested change of headquarter approved

Owner name: AGOMAB THERAPEUTICS (BE)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]